Lifestyle Intervention

PHILADELPHIA — In patients with HF with reduced ejection fraction, a lifestyle intervention improved daily steps by 25%, but that did not translate to improvement in functional capacity, according to the results of the WATCHFUL trial.

DENVER — A primary care-based lifestyle course improved several health behaviors in Appalachia, according to the results of research presented at the American College of Lifestyle Medicine’s annual meeting.

DALLAS — Adults with obesity who received tirzepatide for 72 weeks following a 12-week intensive lifestyle intervention achieved a total mean weight loss greater than 24%, according to data from the SURMOUNT-3 trial.

Top-dose phentermine/topiramate as an adjunct to lifestyle counseling is the most cost-effective strategy for treating adolescents with obesity over 5 years, according to findings from an economic microsimulation model.

Adults with obesity who used tirzepatide for 72 weeks after lifestyle intervention or continuously for 88 weeks achieved a mean weight loss of 26%, according to topline results from two SURMOUNT trials.

PHILADELPHIA — Peripheral artery disease is often the first manifestation of CVD in patients with type 2 diabetes, and represents a “unique” malignant phenotype, a speaker said during the Heart in Diabetes CME Conference.

A gratitude-focused intervention could improve the positive affect of health care workers, according to results of a randomized controlled trial published in Annals of Family Medicine.

Adults who improve from prediabetes to normoglycemia do not have a lower risk for death compared with those with persistent prediabetes, but lifestyle modification can help reduce mortality risk, according to study data.

Calorie-restricted diets, particularly in conjunction with an intensive lifestyle modification program, were associated with increased remission rates among patients with type 2 diabetes, according to a meta-analysis of 28 randomized trials.

Men with prostate cancer are likely to have poor control of modifiable CV risk factors, according to study findings published in JACC: CardioOncology.